tradingkey.logo

Vedanta Biosciences Says VE202 Phase 2 Study In Ulcerative Colitis Did Not Meet Primary Endpoint

ReutersAug 13, 2025 4:32 PM

- Vedanta Biosciences:

  • VEDANTA BIOSCIENCES ANNOUNCES PHASE 2 STUDY OF VE202 IN ULCERATIVE COLITIS DID NOT MEET PRIMARY ENDPOINT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI